Chemistry:Onartuzumab
From HandWiki
Short description: Chemical compound
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Humanized (from mouse) |
| Target | scatter factor receptor kinase |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C4422H6820N1168O1363S31 |
| Molar mass | 99147.88 g·mol−1 |
  (what is this?) (verify) | |
Onartuzumab is a humanized monoclonal antibody designed for the treatment of advanced non-small-cell lung cancer.[1][2][3]
Onartuzumab was developed by Genentech, Inc. It is undergoing clinical trials.[4][5][6][7]
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/onartuzumab.pdf.
- ↑ "MET inhibitors in combination with other therapies in non-small cell lung cancer". Transl Lung Cancer Res 1 (4): 238–53. December 2012. doi:10.3978/j.issn.2218-6751.2012.10.08. PMID 25806189.
- ↑ "Onartuzumab in lung cancer: the fall of Icarus?". Expert Rev Anticancer Ther 15 (5): 487–9. May 2015. doi:10.1586/14737140.2015.1031219. PMID 25818471.
- ↑ "Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors". J Clin Pharmacol 53 (11): 1103–11. November 2013. doi:10.1002/jcph.148. PMID 23922054.
- ↑ "Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer". Clin Lung Cancer 13 (6): 500–4. November 2012. doi:10.1016/j.cllc.2012.05.009. PMID 23063071.
- ↑ "Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer". J. Clin. Oncol. 31 (32): 4105–14. November 2013. doi:10.1200/JCO.2012.47.4189. PMID 24101053.
- ↑ "Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer". Invest New Drugs 33 (3): 632–40. June 2015. doi:10.1007/s10637-015-0227-5. PMID 25777467.
 |  |
